Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6*1 and CYP2D6*10 using cell-based models in vitro

被引：0
|
作者：
Qiang Qu
Jian Qu
Lu Han
Min Zhan
Lan-xiang Wu
Yi-wen Zhang
Wei Zhang
Hong-hao Zhou
机构：
[1] Institute of Clinical Pharmacology,
[2] Hunan Key Laboratory of Pharmacogenetics,undefined
[3] Xiangya Hospital,undefined
[4] Central South University,undefined
[5] Xiangya Hospital,undefined
[6] Central South University,undefined
[7] Institute of Life Sciences,undefined
[8] Chongqing Medical University,undefined
来源：
Acta Pharmacologica Sinica | 2014年 / 35卷
关键词：
CYP2D6; drug interaction; herbal medicine; coptisine; bilobalide; schizandrin; luteolin; puerarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：685 / 696
页数：11
相关论文
共 50 条
  • [21] The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
    Fukuda, T
    Nishida, Y
    Imaoka, S
    Hiroi, T
    Naohara, M
    Funae, Y
    Azuma, J
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (02) : 303 - 308
  • [22] In vitro comparative analysis of metabolic capabilities and inhibitory profiles of selected CYP2D6 alleles on tramadol metabolism
    Nahid, Noor Ahmed
    Kanumuri, Siva Rama Raju
    Sharma, Abhisheak
    Wang, Danxin
    Johnson, Julie A.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2025, 18 (02):
  • [23] The effects of drinking and smoking on the CYP2D6 metabolic capacity
    Vincent-Viry, M
    Fournier, B
    Galteau, MM
    DRUG METABOLISM AND DISPOSITION, 2000, 28 (06) : 617 - 619
  • [24] Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10
    Doki, Kosuke
    Shirayama, Yuki
    Sekiguchi, Yukio
    Aonuma, Kazutaka
    Kohda, Yukinao
    Ieda, Masaki
    Homma, Masato
    PHARMACOGENOMICS, 2020, 21 (18) : 1279 - 1288
  • [25] Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity
    Dalton, Rachel
    Lee, Seung-been
    Claw, Katrina G.
    Prasad, Bhagwat
    Phillips, Brian R.
    Shen, Danny D.
    Wong, Lai Hong
    Fade, Mitch
    McDonald, Matthew G.
    Dunham, Maitreya J.
    Fowler, Douglas M.
    Rettie, Allan E.
    Schuetz, Erin
    Thornton, Timothy A.
    Nickerson, Deborah A.
    Gaedigk, Andrea
    Thummel, Kenneth E.
    Woodahl, Erica L.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 147 - 156
  • [26] Functional Characterization of Cytochrome P450 2D6 (CYP2D6) Allelic Variant CYP2D6*10
    Dong, A. N.
    Ong, C. E.
    Pan, Y.
    Palanisamy, U. D.
    Ismail, R.
    PUBLIC HEALTH GENOMICS, 2015, 18 : 49 - 49
  • [27] Effects of Saikosaponin D on CYP1A2 and CYP2D6 in HepaRG Cells
    Li, Hongfang
    Tang, Yunyan
    Wang, Yang
    Wei, Weipeng
    Yin, Chengchen
    Tang, Fushang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 5251 - 5258
  • [28] Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone
    Cho, Chang-Keun
    Byeon, Ji-Young
    Kang, Pureum
    Park, Jung-In
    Jang, Choon-Gon
    Lee, Seok-Yong
    Choi, Chang-Ik
    Bae, Jung-Woo
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (01) : 59 - 64
  • [29] Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients
    Haslemo, Tore
    Eliasson, Erik
    Jukic, Marin M.
    Ingelman-Sundberg, Magnus
    Molden, Espen
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (01) : 194 - 201
  • [30] Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone
    Chang‑Keun Cho
    Ji-Young Byeon
    Pureum Kang
    Jung-In Park
    Choon-Gon Jang
    Seok-Yong Lee
    Chang-Ik Choi
    Jung‑Woo Bae
    Yun Jeong Lee
    Archives of Pharmacal Research, 2023, 46 : 59 - 64
12345